Volume 66, Issue 4, Pages (October 2014)

Slides:

Advertisements

Similar presentations

Volume 61, Issue 5, Pages (May 2012)

Advertisements

Volume 63, Issue 1, Pages (January 2013)

Volume 62, Issue 3, Pages (September 2012)

Volume 155, Issue 3, Pages (March 1996)

Volume 59, Issue 2, Pages (February 2011)

Volume 71, Issue 2, Pages (February 2017)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Volume 70, Issue 6, Pages (December 2016)

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 68, Issue 4, Pages (October 2015)

Volume 54, Issue 4, Pages (October 2008)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 71, Issue 2, Pages (February 2017)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 65, Issue 6, Pages (June 2014)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 62, Issue 6, Pages (December 2012)

Volume 68, Issue 4, Pages (October 2015)

Volume 59, Issue 2, Pages (February 2011)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 67, Issue 2, Pages (February 2015)

Volume 68, Issue 5, Pages (November 2015)

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 60, Issue 4, Pages (October 2011)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

Yuanshan Cui, Yong Zhang European Urology

Volume 65, Issue 2, Pages (February 2014)

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 65, Issue 6, Pages (June 2014)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Optimising Hormone Therapy in Advanced Disease

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Prostate Cancer Nomograms: An Update

Volume 55, Issue 6, Pages (June 2009)

Volume 49, Issue 4, Pages (April 2006)

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Christian Stief European Urology Supplements

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

Volume 54, Issue 5, Pages (November 2008)

Martin Michel, Jean de la Rosette European Urology Supplements

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

Volume 68, Issue 5, Pages (November 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Axel Heidenreich European Urology Supplements

End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy Jeanette C. Reece,

Volume 51, Issue 5, Pages (May 2007)

Volume 69, Issue 4, Pages (April 2016)

Presentation transcript:

Volume 66, Issue 4, Pages 655-663 (October 2014) Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer Laurent Boccon-Gibod, Peter Albers, Juan Morote, Hendrik van Poppel, Jean de la Rosette, Arnauld Villers, Anders Malmberg, Anders Neijber, Francesco Montorsi European Urology Volume 66, Issue 4, Pages 655-663 (October 2014) DOI: 10.1016/j.eururo.2014.05.037 Copyright © 2014 Terms and Conditions

Fig. 1 Study design. One month was defined as 28 d. PSA=prostate-specific antigen. European Urology 2014 66, 655-663DOI: (10.1016/j.eururo.2014.05.037) Copyright © 2014 Terms and Conditions

Fig. 2 Patient disposition. European Urology 2014 66, 655-663DOI: (10.1016/j.eururo.2014.05.037) Copyright © 2014 Terms and Conditions

Fig. 3 (A) Time to prostate-specific antigen >4 ng/ml during the off-treatment period (OTP) of cycle 1 (full analysis set [FAS]); Kaplan-Meier estimates and 95% confidence intervals (CIs) are provided for FAS OTP. (B) Time to testosterone levels >0.5 ng/ml during cycle 1 (FAS). Kaplan-Meier estimates and 95% CIs are provided for FAS OTP. (C) Time to testosterone levels >2.2 ng/ml during cycle 1 (FAS); Kaplan-Meier estimates and 95% CIs are provided for FAS OTP. (D) Potency during the treatment and corresponding testosterone levels in cycle 1. (E) Mean values for PSA, testosterone, and sexual function during cycle 1. The numbers in the gray area are the number of observations. The sexual function scores are from European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Prostate module 25. IQR=interquartile range; PSA=prostate-specific antigen; OTP=off-treatment period; SD=standard deviation. European Urology 2014 66, 655-663DOI: (10.1016/j.eururo.2014.05.037) Copyright © 2014 Terms and Conditions

Supplemental Fig. 1 – Sexual function based on International Index of Erectile Function (IIEF) Scoring and Sexual Functioning Domain of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Prostate module 25 (EORTC QOL-PR25) during cycle 1. European Urology 2014 66, 655-663DOI: (10.1016/j.eururo.2014.05.037) Copyright © 2014 Terms and Conditions